5.3 Parenteral Nutrition in Oncology: Indications & Management

5.3 Parenteral Nutrition in Oncology: Indications & Management

Quick Summary: Total Parenteral Nutrition (TPN) delivers hypertonic dextrose, amino acids, lipid emulsions, electrolytes, and micronutrients intravenously, bypassing the gastrointestinal tract. TPN is strictly reserved for oncology patients with a non-functional GI tract when support is needed for >7–14 days. Key clinical safety parameters include enforcing a Glucose Infusion Rate (GIR) ≤4.0–5.0 mg/kg/min to prevent hepatic steatosis and holding IV lipids if serum triglycerides exceed 400 mg/dL to prevent acute pancreatitis.

Clinical Indications for PN in Oncology

Parenteral nutrition (PN) provides intravenous macronutrients (amino acids, dextrose, lipid emulsions) and micronutrients (electrolytes, vitamins, trace elements) directly into the systemic circulation, bypassing the gastrointestinal tract entirely. In oncology, PN is a high-risk, high-cost specialized intervention. Both ASPEN and ESPEN guidelines emphasize that PN should never be used routinely in patients with a functional GI tract, as it carries higher risks of central line-associated bloodstream infections (CLABSI), gut mucosal atrophy, sepsis, and metabolic derangements compared to enteral nutrition.

PN is clinically appropriate only when oral and enteral nutrition are impossible or inadequate (<50% of requirements) AND the GI tract is non-functional for an anticipated duration of at least 7 to 14 days.

Valid Indications vs. Contraindications

---

Vascular Access Selection

PN formulations are hypertonic and require specific venous access depending on osmolarity.

---

Compounding Formulations: 2-in-1 vs. 3-in-1 (TNA)

1. 2-in-1 Formulation (Dextrose + Amino Acids)

• Structure: Dextrose and amino acids are compounded together in a clear intravenous bag. Intravenous Fat Emulsion (IVFE) is infused separately as a secondary piggyback line.
• Advantages: Clear solution allows visual inspection for particulate matter or calcium-phosphate precipitation ($Ca \times P$ solubility product). High stability, compatible with more additive medications.

2. 3-in-1 Formulation / Total Nutrient Admixture (TNA)

• Structure: Dextrose, amino acids, and IVFE are compounded together in a single opaque lipid-containing bag.
• Advantages: Reduced nursing administration time, single volumetric pump, reduced catheter hub manipulations (lowering CLABSI risk), simplified home PN management.
• Disadvantages: Opaque white appearance masks precipitates; risk of lipid emulsion cracking (separation of oil phase) if pH drops <5.0 or high divalent cation concentrations ($Ca^{2+}, Mg^{2+}$) are added.

---

Macronutrient Dosing & Mandatory Safety Limits

1. Carbohydrate (Dextrose Monohydrate = 3.4 kcal/g)

• Glucose Infusion Rate (GIR) Calculation: $\text{GIR (mg/kg/min)} = \frac{\text{Total Dextrose (g)} \times 1,000}{\text{Weight (kg)} \times 1,440 \text{ min}} \quad \text{or} \quad \frac{\text{IV Infusion Rate (mL/hr)} \times \%\text{Dextrose} \times 1,000}{\text{Weight (kg)} \times 6,000}$ Both forms convert grams of dextrose to milligrams and divide by minutes and kilograms; the 3.4 kcal/g factor converts dextrose monohydrate to calories and must not appear in a GIR calculation. Check the second form on a 70 kg patient receiving D20 at 100 mL/hr: $(100 \times 20 \times 1,000) \div (70 \times 6,000) = 4.76 \text{ mg/kg/min}$ — at the ceiling, not below it.
• GIR Upper Limit: ≤4.0 to 5.0 mg/kg/min in stable patients (≤3.0 mg/kg/min in critical illness or severe hyperglycemia). Exceeding this rate induces de novo lipogenesis, hepatic steatosis, hypercapnia (increased $VCO_2$), and severe hyperglycemia.

2. Protein (Amino Acids = 4.0 kcal/g)

• Dosing: 1.2 to 2.0 g/kg/day based on dry baseline weight. Higher ranges (1.5–2.0 g/kg/day) are required for HSCT recipients, severe mucositis, or surgical wound healing.

3. Lipid Emulsions (IVFE = 10 kcal/g for 20% lipid emulsion)

• Soybean Oil IVFE (Intralipid): Pure omega-6 fatty acids; pro-inflammatory at high doses.
• SMOFlipid: 4-oil blend (30% Soybean oil, 30% Medium-Chain Triglycerides, 25% Olive oil, 15% Fish oil). Rich in omega-3 EPA/DHA; reduces hepatotoxicity and parenteral nutrition-associated liver disease (PNALD).
• Triglyceride Threshold: Check baseline serum triglycerides. If serum triglycerides exceed 400 mg/dL, IVFE must be held or reduced to 500 mL 10% IVFE once or twice weekly solely to prevent essential fatty acid deficiency (EFAD).

---

Worked Example: TPN Order Calculation

Patient Scenario

A 55-year-old female (weight: 60 kg) with severe acute GI GVHD requires TPN (Target: 1,800 kcal/day, 90 g protein/day).

• Protein: 90 g Amino Acids ($90 \times 4 = 360 \text{ kcal}$).
• Remaining Calorie Need: $1,800 - 360 = 1,440 \text{ kcal}$.
• Lipid: 250 mL 20% SMOFlipid ($250 \text{ mL} \times 2.0 \text{ kcal/mL} = 500 \text{ kcal}$; $500 / 10 = 50 \text{ g lipid} = 0.83 \text{ g/kg/day}$, safe).
• Dextrose Calorie Need: $1,440 - 500 = 940 \text{ kcal} \rightarrow 940 / 3.4 = 276.5 \text{ g Dextrose}$.
• Verify GIR: $\text{GIR} = \frac{276.5 \text{ g} \times 1,000}{60 \text{ kg} \times 1,440 \text{ min}} = \frac{276,500}{86,400} = 3.20 \text{ mg/kg/min}$ Result: GIR of 3.20 mg/kg/min is safely below the maximum cap of 4.0–5.0 mg/kg/min.

---

Infection Prevention & PN Weaning Protocol

• Dedicated central line lumen exclusively for PN infusion (never use PN lumen for blood draws or medication flushes).
• Strict aseptic technique during line hookup, utilizing chlorhexidine skin prep and alcohol-impregnated caps.
• Change 2-in-1 administration tubing every 96 hours; change 3-in-1 and separate lipid tubing every 24 hours.
• PN Weaning Protocol: As oral or enteral intake reaches >60% of total calculated energy and protein needs, PN can be safely tapered and discontinued.